11 April 2024 1730 BST
Results of Annual General
Meeting held on 11 April 2024
AstraZeneca PLC announced the
results of the voting at its Annual General Meeting (AGM) today. As
proposed in the Notice of AGM, all Resolutions were decided by poll
vote. Resolutions 11 - 14 were passed as special resolutions; all
other resolutions were passed as ordinary resolutions.
|
|
Resolution
|
Votes for
|
% of votes
cast
|
Votes
against
|
% of votes
cast
|
Votes cast in
total
|
Total votes cast as a % of
issued share capital
|
Votes
withheld
|
|
1
|
To receive the Company's Accounts,
the Reports of the Directors and Auditor and the Strategic Report
for the year ended 31 December 2023
|
1,205,690,871
|
99.88
|
1,470,816
|
0.12
|
1,207,161,687
|
77.87%
|
9,700,968
|
|
2
|
To confirm dividends
|
1,215,177,590
|
99.94
|
790,189
|
0.06
|
1,215,967,779
|
78.44%
|
894,978
|
|
3
|
To reappoint PricewaterhouseCoopers
LLP as Auditor
|
1,208,377,872
|
99.36
|
7,843,545
|
0.64
|
1,216,221,417
|
78.45%
|
642,048
|
|
4
|
To authorise the Directors to agree
the remuneration of the Auditor
|
1,215,717,786
|
99.98
|
279,816
|
0.02
|
1,215,997,602
|
78.44%
|
722,222
|
|
5a
|
To re-elect Michel Demaré as a
Director
|
1,197,325,871
|
98.49
|
18,416,788
|
1.51
|
1,215,742,659
|
78.42%
|
1,120,559
|
|
5b
|
To re-elect Pascal Soriot as a
Director
|
1,206,729,787
|
99.26
|
9,036,742
|
0.74
|
1,215,766,529
|
78.42%
|
1,098,706
|
|
5c
|
To re-elect Aradhana Sarin as a
Director
|
1,212,225,383
|
99.71
|
3,509,122
|
0.29
|
1,215,734,505
|
78.42%
|
1,129,532
|
|
5d
|
To re-elect Philip Broadley as a
Director
|
1,197,937,103
|
98.54
|
17,773,671
|
1.46
|
1,215,710,774
|
78.42%
|
1,153,360
|
|
5e
|
To re-elect Euan Ashley as a
Director
|
1,213,332,278
|
99.80
|
2,375,199
|
0.20
|
1,215,707,477
|
78.42%
|
1,156,567
|
|
5f
|
To re-elect Deborah DiSanzo as a
Director
|
1,215,396,504
|
99.97
|
318,525
|
0.03
|
1,215,715,029
|
78.42%
|
1,149,106
|
|
5g
|
To re-elect Diana Layfield as a
Director
|
1,215,424,019
|
99.98
|
292,514
|
0.02
|
1,215,716,533
|
78.42%
|
1,147,602
|
|
5h
|
To elect Anna Manz as a
Director
|
1,215,297,866
|
99.97
|
417,067
|
0.03
|
1,215,714,933
|
78.42%
|
1,149,091
|
|
5i
|
To re-elect Sheri McCoy as a
Director
|
1,158,846,767
|
95.32
|
56,874,293
|
4.68
|
1,215,721,060
|
78.42%
|
1,142,920
|
|
5j
|
To re-elect Tony Mok as a
Director
|
1,215,346,936
|
99.97
|
346,157
|
0.03
|
1,215,693,093
|
78.42%
|
1,170,931
|
|
5k
|
To re-elect Nazneen Rahman as a
Director
|
1,191,449,316
|
98.59
|
16,988,178
|
1.41
|
1,208,437,494
|
77.95%
|
8,426,242
|
|
5l
|
To re-elect Andreas Rummelt as a
Director
|
1,215,395,253
|
99.97
|
314,359
|
0.03
|
1,215,709,612
|
78.42%
|
1,154,412
|
|
5m
|
To re-elect Marcus Wallenberg as a
Director
|
947,479,100
|
77.93
|
268,252,536
|
22.07
|
1,215,731,636
|
78.42%
|
1,132,416
|
|
6
|
To approve the Annual Report on
Remuneration for the year ended 31 December 2023
|
1,158,470,360
|
95.32
|
56,835,406
|
4.68
|
1,215,305,766
|
78.40%
|
1,558,941
|
|
7
|
To approve the Directors'
Remuneration Policy
|
761,702,826
|
64.43
|
420,514,520
|
35.57
|
1,182,217,346
|
76.26%
|
34,645,873
|
|
8
|
To approve amendments to the
AstraZeneca Performance Share Plan 2020
|
769,577,451
|
65.34
|
408,204,003
|
34.66
|
1,177,781,454
|
75.97%
|
39,083,170
|
|
9
|
To authorise limited political
donations
|
1,184,223,861
|
98.00
|
24,219,787
|
2.00
|
1,208,443,648
|
77.95%
|
8,278,265
|
|
10
|
To authorise the Directors to allot
shares
|
1,129,625,915
|
92.94
|
85,836,406
|
7.06
|
1,215,462,321
|
78.41%
|
1,259,562
|
|
11
|
To authorise the Directors to
disapply pre-emption rights
|
1,044,559,011
|
85.95
|
170,708,848
|
14.05
|
1,215,267,859
|
78.39%
|
1,454,048
|
|
12
|
To authorise the Directors to
further disapply pre-emption rights for acquisitions and specified
capital investments
|
997,629,834
|
82.33
|
214,143,713
|
17.67
|
1,211,773,547
|
78.17%
|
4,948,031
|
|
13
|
To authorise the Company to purchase
its own shares
|
1,205,828,976
|
99.23
|
9,306,860
|
0.77
|
1,215,135,836
|
78.38%
|
1,585,923
|
|
14
|
To reduce the notice period for
general meetings
|
1,131,157,449
|
93.07
|
84,269,754
|
6.93
|
1,215,427,203
|
78.40%
|
1,294,801
|
A copy of the resolutions passed at
the AGM (other than resolutions concerning ordinary business) has
been submitted to the National Storage Mechanism for publication,
and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Statement in connection with
resolutions 5m, 7 and 8
AstraZeneca is pleased that all
resolutions were supported at today's Annual General Meeting. In
particular, the Board thanks the majority of our shareholders who
have supported the Remuneration Policy (the Policy) and will
continue to engage with our shareholders and the proxy advisors to
explain our need for global benchmarks and pay for performance,
which is driven by the Policy.
We will publish an update on the
engagement with shareholders on resolutions 5m, 7 and 8 and on any
action taken as a result within six months of today's AGM, in
accordance with the UK Corporate Governance Code.
Issued capital
As at 9 April 2024, the number of
issued shares of the Company was 1,550,231,084 ordinary shares,
which was the total number of shares entitling the holders to
attend and vote for or against all of the resolutions at the AGM.
In accordance with the Company's Articles of Association, on a poll
every member present in person or by proxy has one vote for every
share held.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is
a global, science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit
astrazeneca.com
and follow the Company on social media
@AstraZeneca.
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC